Antares Pharma clinches Teva deal for new drug delivery injector:
This article was originally published in Clinica
Drug delivery systems developer Antares Pharma has signed an agreement to develop and supply a new disposable injection device to Israeli drugs company Teva Pharmaceutical Industries. The exclusive agreement requires Teva to buy all its delivery devices from Anatares for use with an undisclosed drug that is subject to regulatory approval. Exton, Pennsylvania-based Antares will receive an upfront cash payment, milestone fees, royalties and a transfer price for the device. The finished product will be marketed in the US and Canada, said Antares. The agreement also gives Teva an option for rights to the product in other countries.